Episode 19: A Between the Biotech Waves Conversation with JeanFrancois Formela, Partner at Atlas Venture & multi-biotech company founder
Between the Biotech Waves
00:00
Gene Therapy, Gene Editing - Is There a Catch-Up?
I think there's still a lot of work to be done on the delivery side and how far we've moved from a modality and overall editing standpoint. I remember being shocked at the headline, you know, whether it's an end point of set news or one of those saying ISER is ruling that product was cost effective. The current total cost of such vision today in the absence of that treatment is way higher than 2.3 million dollars. And Gilead got a really bad deal, even though they were able to get $1,000 for flax.
Transcript
Play full episode
